Session

Back to Programme Overview

Prostate cancer biomarkers: Technical advances and clinical implications

Poster Session 46

  • Location:
    Room Stockholm, North Hall (Level 1)
  • Chairs:
     M.G.K. Cumberbatch, Sheffield (GB)
     S. Füssel, Dresden Johannstadt Nord (DE)
     K.A. Tasken, Oslo (NO)
  • Aims and objectives of this session

    Investigations on circulating tumor cells have been widely used in prostate cancer biomarker studies. Further improvements in biomarker assessment include application of MRI. New technical tools will be presented in the session.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 616
Molecular characterization of magnetic resonance imaging visible and invisible prostate cancer: Biological insights and therapeutic implications

By: Salami S.1, Hovelson D.2, Udager A.2, Lee M.1, Curci N.3, Kaplan J.2, George A.1, Davenport M.3, Tomlins S.2, Palapattu G.1

Institutes: 1University of Michigan, Dept. of Urology, Ann Arbor, United States of America, 2University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, 3University of Michigan, Dept. of Radiology, Ann Arbor, United States of America

617
A combination of new protein biomarkers reduces unneeded prostate biopsies and improves the detection of prostate cancer: Findings of a recent study

By: Steuber T.1, Tennstedt P.1, Macagno A.2, Golding B.2, Schiess R.2, Gillessen S.3

Institutes: 1Universitätsklinikum Hamburg-Eppendorf, Martini-Clinic, Prostate Cancer Center, Hamburg, Germany, 2Proteomedix, Dept. of Biotechnology, Schlieren, Switzerland, 3Cantonal Hospital St. Gallen, Dept. of Oncology, St. Gallen, Switzerland

* 618
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence

By: Braadland P.R.1, Giskeødegård G.2, Guldvik I.J.3, Sandsmark E.2, Bertilsson H.4, Euceda L.2, Hansen A.2, Grytli H.H.3, Katz B.5, Svindland A.5, Berge V.6, Eri L.M.6, Nygård S.7, Bathen T.2, Tasken K.A.1, Tessem M-B.2

Institutes: 1Oslo University Hospital and University of Oslo, Institute of Cancer Research and Institute of Clinical Medicine, Oslo, Norway, 2Norwegian University of Science and Technology (NTNU), Dep. of Circulation and Medical Imaging, Trondheim, Norway, 3Oslo University Hospital, Institute of Cancer Research, Oslo, Norway, 4St.Olav’s Hospital and Norwegian University of Science and Technology (NTNU), Dep. of Urology and Dep. of Circulation and Medical Imaging, Trondheim, Norway, 5Oslo University Hospital, Dep. of Pathology, Oslo, Norway, 6Oslo University Hospital, Dep. of Urology, Oslo, Norway, 7Oslo University Hospital, Institute of Informatics, Oslo, Norway

619
Incidence rates and cancer control outcomes of contemporary primary neuroendocrine prostate cancer: Analysis of SEER database

By: Zaffuto E.1, Zanaty M.2, Bondarenko H.D.2, Pompe R.3, Dell’Oglio P.1, Gandaglia G.1, Fossati N.1, Stabile A.1, Zorn K.C.4, Montorsi F.1, Briganti A.1, Karakiewicz P.I.2

Institutes: 1IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology; URI, Milan, Italy, 2University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, 3Prostate Cancer Center Hamburg-Eppendorf, Martini-Clinic, Hamburg, Germany, 4University of Montreal Health Center, Dept. of Surgery, Section of Urology, Montreal, Canada

620
Identification of tumour-specific biomarkers associated with serum lactate dehydrogenase levels for predicting clinical responses to docetaxel chemotherapy in mCRPC

By: Hiew K.1, Hart C.A.2, Bokobza S.3, Elliott T.4, Smith N.3, Brown M.2, Clarke N.5

Institutes: 1Salford Royal NHS Foundation Trust, Dept. of Urology, Salford, United Kingdom, 2The University of Manchester, Genito Urinary Cancer Research Group, Manchester, United Kingdom, 3AstraZeneca, R&D, Oncology IMed, Macclesfield, United Kingdom, 4Christie Hospital NHS Foundation Trust, Dept. of Oncology, Manchester, United Kingdom, 5Christie Hospital NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom

621
Elevated preoperative neutrophil–lymphocyte ratio predicts upgrading at radical prostatectomy

By: Özsoy M.1, Moschini M.1, Fajkovic H.1, Soria F.1, Seitz C.1, Klatte T.1, Kilian G.1, Briganti A.2, Karakiewicz P.3, Roupret M.4, Kramer G.1, Shariat S.1

Institutes: 1Medical University of Vienna, Dept. of Urology, Vienna, Austria, 2Vita-Salute University, San Raffaele Scientific Institute, Urological Research Institute, Milan, Italy, 3University of Montreal, Health Centre, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, 4Pitié-Salpétrière Hospital, Dept. of Urology, Paris, France

622
Perioperative search for circulating tumor cells in patients undergoing prostate brachytherapy for clinically nonmetastatic prostate cancer

By: Tsumura H.1, Satoh T.1, Tabata K-I.1, Ishiyama H.2, Takenaka K.2, Sekiguchi A.2, Kitano M.2, Hayakawa K.2, Iwamura M.1

Institutes: 1Kitasato University School of Medicine, Dept. of Urology, Sagamihara, Japan, 2Kitasato University School of Medicine, Dept. of Radiology and Radiation Oncology, Sagamihara, Japan

623
Purification of urinary extracellular vesicles for uro-oncological biomarker studies using an iodixanol (Optiprep™) density gradient

By: Dhondt B.1, Vergauwen G.2, Van Deun J.2, Geeurickx E.2, Claeys T.1, Poelaert F.1, Buelens S.1, Hendrix A.2, De Wever O.2, Lumen N.1

Institutes: 1Universitair Ziekenhuis Gent, Dept. of Urology, Ghent, Belgium, 2Universitair Ziekenhuis Gent, Dept. of Radiation Oncology and Experimental Cancer Research, Ghent, Belgium

624
Prostate cancer genomics: Identification of prognostic markers from the bone marrow

By: Bier S.1, Hennenlotter J.1, Haerle U.2, Karpatsi E.1, Stenzl A.1, Todenhoefer T.1, Schmees C.2

Institutes: 1Eberhard-Karls-University Tuebingen, Dept. of Urology, Tübingen, Germany, 2Natural and Medical Sciences Institute, Dept. of Tumor Biology, Tübingen, Germany

625
Increased CCR4-positive regulatory T cells in biopsy specimens of poor prognostic prostate cancer

By: Watanabe M.1, Kanao K.1, Suzuki S.2, Muramatsu H.1, Morinaga S.1, Kajikawa K.1, Kobayashi I.1, Nishikawa G.1, Kato Y.1, Nakamura K.1, Yoshikawa K.3, Ueda R.2, Sumitomo M.1

Institutes: 1Aichi Medical University, Dept. of Urology, Nagakute, Japan, 2Aichi Medical University, Dept. of Tumor Immunology, Nagakute, Japan, 3Aichi Medical University, Division of Advanced Research Promotion, Nagakute, Japan

626
Identification and validation of a novel blood-based biomarker of aggressive prostate cancer

By: Guldvik I.J.1, Grytli H.2, Zuber V.3, Thiede B.4, Saatcioglu F.4, Gislefoss R.5, Kvåle R.5, George A.6, Gnanapragasam V.7, Grönberg H.8, Wiklund F.8, Neal D.9, Mills I.10, Taskén K. A.2

Institutes: 1Oslo University Hospital/Centre For Molecular Medicine Norway, Dept. of Prostate Cancer, Oslo, Norway, 2Oslo University Hospital, Dept. of Tumorbiology, Oslo, Norway, 3Centre For Molecular Medicine (Norway), University of Oslo and Oslo University Hospital, Dept. of Prostate Cancer, Oslo, Norway, 4University of Oslo, Dept. of Biosciences, Oslo, Norway, 5Oslo University Hospital, Dept. of Cancer Registry of Norway, Oslo, Norway, 6University of Cambridge, Dept. of Surgery, Cambridge, United Kingdom, 7University of Cambridge, Translational Prostate Cancer Group, Cambridge, United Kingdom, 8Karolinska Institute, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, 9University of Oxford, Dept. of Surgical Sciences, Oxford, United Kingdom, 10Queen’s University Belfast/Centre For Molecular Medicine Norway, Dept. of Prostate Cancer UK/Movember Centre of Excellence For Prostate Cancer Research, Centre For Cancer Research and Cell Biology, Belfast, Ireland

New protein biomarkers in prostate cancer
 S. Füssel, Dresden Johannstadt Nord (DE)